Prelude Therapeutics

PRLD Micro Cap

Healthcare · Biotechnology

Updated: Apr 5, 2026, 17:43 UTC

$3.46

+0.29% today

52W: $0.61 – $4.22

52W Low: $0.61 Position: 78.9% 52W High: $4.22

🔗 Compare Brokers

Key Metrics

P/E Ratio

—

Price-to-Earnings

Forward P/E

—

Forward Price/Earnings

P/S Ratio

17.92x

Price-to-Sales

EV/EBITDA

—

Enterprise Value/EBITDA

Div. Yield

—

Annual dividend yield

Market Cap

$217.5M

Market Capitalization

Revenue Growth

41%

YoY Revenue Growth

Profit Margin

—

Net profit margin

ROE

-99.45%

Return on Equity

Beta

0.71

Market sensitivity

Short Interest

18.97%

% of float sold short

Avg. Volume

342,039

Average daily volume

Valuation Analysis

Signal

N/A

vs. S&P 500 avg P/E (24.7x)

Analyst Consensus

None

3 analysts

Avg. Price Target

$5.17

+49.33% upside

Target Range

$4.50 – $6.00

About the Company

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Sector: Healthcare Industry: Biotechnology Country: United States Employees: 79 Exchange: NMS